ArticleScience advances2025
Fluidic microgel assemblies with enhanced oral delivery of biologics alleviate colonic inflammation in murine and canine models.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Water-responsive injectable hydrogel achieving rapid in situ gelation and long-term colonic mucoadhesion for efficient fecal microbiota transplantation.Bioactive materials · 2027Article
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of oral delivery of biologic drugs for inflammatory bowel disease (IBD) treatment is substantially compromised by the swift enzymatic degradation and insufficient retention of biologics in the gastrointestinal tract. Here, we report a simple method for fabricating fluidic microgel assemblies (FMGAs) by introducing the hydrogen bonds between the microgel surfaces. These FMGAs with water content of 77% are flowable yet immiscible with water. Upon oral administration, these FMGAs form a large-area physical adhesive coating on the intestinal surface, extending intestinal retention time to at least 48 hours. The intermicrogel spaces within the assemblies can efficiently harbor therapeutic biologics (such as exosomes and TNFα antibody), protect them from the harsh intestinal microenvironment, and enable efficient delivery to intestinal lesion sites to restore intestinal barrier function and microbiota diversity in mouse and beagle models of IBD. We believe that the fluidic microgel assembly strategy holds great promise for oral delivery of labile biologics for the treatment of diverse gastrointestinal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.